 (BrJ Ophthalmol 1995; 79: 150-152) 
Interferon alfa has been used to treat several disorders including renal cell carcinoma, macular degeneration, and chronic viral hepatitis. 1- 6 Guyer and associates2 have reported on retinal ischaemia associated with the use of interferon alfa in the treatment of various illnesses. Isaka and co-workers, 3 Imaizumi and associates,5 and Futami et al6 According to their fundus condition before interferon therapy, patients in group B were further divided into group B1, which included three patients without retinopathy, and group B2, which contained three patients who had retinal microaneurysms. All patients were followed up ophthalmically for more than 8 months after interferon alfa therapy began.
Excluded from the present study were patients who had hypertension, severe arteriosclerosis, or collagen disease before the start of therapy and those with previous ocular trauma or surgery.
We used Student's t test for statistical evaluation. Results were assumed to be significant if p<0-05.
Results
The 37 non-diabetic patients in group A were subdivided into three smaller groups, at a mean duration of 8 weeks after start of therapy. Of six eyes, two had microaneurysms, two had cotton wool spots, and two had cotton wool spots, microaneurysms, and haemorrhages. The retinopathy in group B 1 remained stable during therapy. Of six eyes of group B2, which had only microaneurysms before interferon therapy, four developed cotton wool spots after treatment, and two developed cotton wool spots and haemorrhages. Retinopathies in 18 eyes of group A2 and in two eyes of group B 1 resolved after the interferon therapy was discontinued.
Discussion
Isaka and co-workers3 have suggested that thrombocytopenia may be involved in the pathogenesis of interferon associated retinopathy. In our present study, however, we found no significant difference in platelet counts between groups Al and A2 or between groups Al and B 1. It is unlikely that the red blood cell counts, haemoglobin levels, glutamic oxaloacetic transaminase levels, glutamate pyruvate transaminase levels, and blood pressures were related to the development of retinopathy in our patients. It is likely that the high dose and long duration of interferon therapy may have been associated with the development of retinopathy. However, the exact mechanism of retinopathy in patients with chronic viral hepatitis receiving interferon therapy is unclear. Subconjunctival haemorrhage reportedly develops in patients with minor local trauma, systemic hypertension, and acute conjunctivitis.7 Our patients in group A3 had no such disorders. It is possible that the subconjunctival haemorrhages seen in group A3 patients may have been related to the interferon therapy.
Guyer and associates2 have reported that retinal complications may be reversible when treatment is stopped. In most of our nondiabetic patients in group A2, the retinopathy disappeared after the interferon was stopped. In most of our diabetic patients in group B 1 and B2, however, the retinopathy continued.
Our findings showed that the patients' good visual acuities remained unchanged, even when retinopathy occurred. Guyer and co-workers2 described a case of visual loss associated with interferon therapy. Ophthalmologists should be aware that retinopathy and subconjunctival haemorrhage may develop in patients with chronic viral hepatitis receiving interferon therapy.
